Radiation plus AK104 for esophagus cancer that returned or spread
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial studies whether combining a focused type of radiation (SBRT) with AK104 can shrink or control esophageal squamous cell cancer that has come back or spread. It may help by targeting tumors with radiation while AK104 supports the treatment approach for PD-1–naïve patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your esophagus cancer must be squamous cell type, and it must have returned or spread to measurable spots that doctors can track on scans.
- You need at least two measurable tumor areas, and at least one must be treatable with the study radiation.
- You should not have had PD-1 immunotherapy before.
- Your heart, lung, liver, and kidney health must be stable enough for treatment (no serious recent worsening, and specific lab ranges must be met).
- You must be able to understand the study and sign consent, and you must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug called AK104 (cadonilimab) combined with low-dose radiation for people with head and neck or nasopharyngeal cancer that has come back or spread and no longer responds to first treatment. The goal is to see if this combination can shrink tumors or stop them from growing.
This trial studies whether adding an anti-PD-1 immunotherapy (with chemotherapy) together with radiation can help people with advanced esophageal squamous cell cancer. It’s for cases where surgery or standard definitive chemoradiation can’t be done, or the cancer has spread to distant sites.
This trial tests a new combination therapy for people with recurrent or metastatic esophageal squamous cell carcinoma. First, you receive immunotherapy (cadonilimab) and a targeted drug (anlotinib), followed by radiation. The goal is to see if this approach helps control the cancer.
This trial combines a special high-dose radiation (SBRT) with immunotherapy to treat esophageal cancer that has spread to a few spots in the body (up to 5 spots in up to 3 organs). The goal is to see if this approach can better control the cancer.
This trial tests a new immunotherapy drug, AK104, for people with stage III non-small cell lung cancer that cannot be removed with surgery. It is for those who have finished chemoradiotherapy and have not gotten worse.
This trial tests a short course of radiation combined with two drugs (raltitrexed and tislelizumab) for people with esophageal cancer that has returned after standard treatment. The goal is to see if these combinations can shrink tumors and improve survival.
Hear when a new Recurrent or Metastatic Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.